Objective:To study the effect of Qianggan Pills combined with antiviral treatment on the fibrosis indexes, immune and inflammatory response in patients with compensated hepatitis b cirrhosis.Methods:A total of 88 pati...Objective:To study the effect of Qianggan Pills combined with antiviral treatment on the fibrosis indexes, immune and inflammatory response in patients with compensated hepatitis b cirrhosis.Methods:A total of 88 patients with compensated hepatitis b cirrhosis treated in our hospital between April 2013 and March 2016 were collected and divided into observation group and control group according to single blind randomized control. Observation group of patients accepted Qianggan Pills combined with antiviral treatment and control group of patients received antiviral treatment alone. After 6 months of treatment, chemiluminescence method was used to detect serum fibrosis indexes, flow cytometer was used to detect peripheral blood T lymphocyte subset levels, and enzyme-linked immunosorbent assay (ELISA) was used to detect serum levels of inflammatory factors.Results: Before treatment, differences in fibrosis indexes, immune and inflammatory response indexes were not statistically significant between two groups of patients;after 6 months of treatment, serum LN, HA andⅣ-C levels of observation group were lower than those of control group, peripheral blood CD3+ and CD4+T lymphocyte levels as well as CD4+/CD8+ ratio were higher than those of control group, and CD8+ T lymphocyte level was lower than that of control group;serum PCT and CRP levels were lower than those of control group while IL-10 and IL-13 levels were higher than those of control group.Conclusion:Qianggan Pills combined with antiviral treatment can inhibit the fibrosis process, strengthen the body's immune function and also relieve systemic inflammatory response in patients with compensated hepatitis b cirrhosis.展开更多
Objective： To observe the therapeutic effect and safety of Qianggan Capsule （强肝胶囊, QGC） in treating non-alcoholic fatty liver disease （NAFLD）, using potyene phosphatidylcholine capsule （PPC） as a reference....Objective： To observe the therapeutic effect and safety of Qianggan Capsule （强肝胶囊, QGC） in treating non-alcoholic fatty liver disease （NAFLD）, using potyene phosphatidylcholine capsule （PPC） as a reference. Metheds： Eighty-eight patients with NAFLD were randomly assigned to two groups, 45 in the treatment group treated with QGC and 43 in the control group treated with PPC. The course of treatment tasted for 6 months. Changes in liver function, blood lipids, and iconographic indexes before and after treatment were observed, and clinical efficacy was evaluated. Results： In the treatment group, alanine aminotransferase （ALT） was towered significantly from 56.02 ± 32.59 lUlL before treatment to 38.27 ± 22.68 IU/L after treatment, and CT liver/spleen ratio significantly increased from 0.69± 0.18 to 0.91 ± 0.25, showing statistical significance （P〈0.05）; in contrast, the corresponding changes of the two indexes in the control group were 56.56 ±26.33 IU/L to 49.67 ± 26.22 IU/L, and 0.66± 0.20 to 0.75 ± 0.24, respectively, the pre-post treatment difference showing insignificant difference （P〉0.05）. No severe adverse reactions occurred during the whole treatment course. Conclusion： QGC is an effective and safe remedy for the treatment of NAFLD.展开更多
Objective:To explore the clinical therapeutic effect of Qianggan Capsule(QGC)in treating chronic hepatitis B with liver fibrosis from the pathological aspect.Methods:Sixty three patients of chronic hepatitis B with li...Objective:To explore the clinical therapeutic effect of Qianggan Capsule(QGC)in treating chronic hepatitis B with liver fibrosis from the pathological aspect.Methods:Sixty three patients of chronic hepatitis B with liver fibrosis were randomly divided into the treated group(n=45)and the control group(n=18).Both groups were treated with general liver protective drugs,such as Glucurone and vitamins B complex for 6 months.To the treated group,QGC was used additionally.The levels of serum alanine transaminase and liver fibrosis indexes including hyaluronic acid(HA),collagen typeⅣ(CⅣ)and laminin(LN)as well as the pathological examination of liver biopsy were observed before and after treatment.Results:The liver cirrhosis indexes,HA,CⅣand LN,were improved significantly in the treated group after treatment,P<0.05.The liver function improvement rate in the treated group and the control group was 90.3%and 66.7%respectively,comparison of the two groups showed insignificant difference,P>0.05.Pathological examination showed that the effective rate of treatment on liver inflammatory necrosis activity grade in the treated group was 57.8%and that on liver fibrosis stage was 75.6%,which were significantly improved as compared with those before treatment(P<0.05 and P<0.01),while in the control group,no significant improvement was found after treatment(P>0.05).Conclusion:QGC has marked effects in reversing liver fibrosis and alleviating hepatic inflammatory necrosis in patients of chronic hepatitis B with liver fibrosis,and could lower the serum liver fibrosis related indexes effectively.展开更多
Objective: Qianggan(QG) extract is a patented traditional Chinese medicine that has been widely used for the clinical treatment of nonalcoholic steatohepatitis(NASH). However, its mechanism remains unclear. Methods: T...Objective: Qianggan(QG) extract is a patented traditional Chinese medicine that has been widely used for the clinical treatment of nonalcoholic steatohepatitis(NASH). However, its mechanism remains unclear. Methods: The efficacy of QG was evaluated in mice with methionine-and-choline-deficient diet-induced NASH by measuring serum alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels and by H and E staining of liver sections. Microarray and bioinformatics analyses were performed to obtain hepatic micro RNA(mi RNA) and m RNA expression profiles and to mine potential mechanisms and therapeutic targets. Furthermore, representative mi RNA and m RNA expression levels were validated by quantitative real-time polymerase chain reaction(q RT-PCR). Results: QG extract significantly improved NASH. Twelve differentially expressed mi RNAs and 1124 differentially changed m RNAs were identified as potential targets of QG extract. Integrated analysis detected 976 mi RNA–m RNA regulatory pairs, and networks including 11 mi RNAs and 427 m RNAs were constructed by Cytoscape. Hub nodes including mi R-7050-5p, mi R-212-3p, Bcl2l11, and Kras were filtered out. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses revealed that 427 m RNAs were enriched in pathways including apoptotic process, immune response, Fox O signaling pathway, and natural killer cell-mediated cytotoxicity. We also constructed a protein–protein interaction network with 254 nodes, and identified hub genes including Kras, Fasl, and Ncam1. Finally, the results of q RT-PCR were in good accordance with microarray data. Conclusion: This study identified important hub mi RNAs and m RNAs involved in the mechanism of QG extract and which might provide potential therapeutic targets for patients with NASH.展开更多
基于多靶点虚拟筛选、网络药理学分析和体外实验,探讨强肝胶囊(QGC)治疗非酒精性脂肪性肝病(NAFLD)的潜在作用机制。利用基于PPARα/γ、FXR及sEH的多靶点虚拟筛选选出QGC中具有治疗NAFLD的活性成分,运用网络药理学预测活性成分靶点、...基于多靶点虚拟筛选、网络药理学分析和体外实验,探讨强肝胶囊(QGC)治疗非酒精性脂肪性肝病(NAFLD)的潜在作用机制。利用基于PPARα/γ、FXR及sEH的多靶点虚拟筛选选出QGC中具有治疗NAFLD的活性成分,运用网络药理学预测活性成分靶点、疾病相关靶点,筛选调控疾病的关键靶点,通过Discovery Studio 2020软件和Gromacs软件对关键活性成分和关键靶点进行分子对接和分子动力学模拟分析。最后,通过实验验证QGC中的关键活性成分对肝细胞脂肪变性的改善作用。多靶点虚拟筛选得到235个QGC活性成分,网络药理学分析得到320个成分-疾病共同靶点。分子对接结果表明,芹菜素、异鼠李素、迷迭香酸、大黄素甲醚、木犀草素与关键靶点PTPN1、PPARα、PPARγ、AR具有良好的结合能力。分子动力学模拟进一步验证了迷迭香酸、大黄素甲醚等化合物与关键靶点具有良好的结合稳定性。体外实验结果显示,5个关键活性成分均能改善HepG2细胞的脂肪变性,其中异鼠李素、迷迭香酸、大黄素甲醚改善细胞脂肪变性模型的效果最佳。本研究通过多层面探讨,为QGC在NAFLD治疗中的开发和应用提供理论依据。展开更多
目的观察强肝胶囊对非酒精性脂肪性肝病(NAFLD)患者肝纤维化评分和胰岛素抵抗指数的影响。方法选取2014年8月-2015年7月在上海市第八人民医院就诊的NAFLD患者85例,随机分为治疗组(n=45)和对照组(n=40)。治疗组给予强肝胶囊,对照组给予...目的观察强肝胶囊对非酒精性脂肪性肝病(NAFLD)患者肝纤维化评分和胰岛素抵抗指数的影响。方法选取2014年8月-2015年7月在上海市第八人民医院就诊的NAFLD患者85例,随机分为治疗组(n=45)和对照组(n=40)。治疗组给予强肝胶囊,对照组给予多烯磷脂酰胆碱胶囊,2组疗程均为24周。观察2组治疗前后血清转氨酶(AST、ALT)、稳态模型胰岛素抵抗指数(HOMA-IR)以及NAFLD肝纤维化评分(NAFLDFS)的变化。计量资料组间比较采用成组t检验,组内治疗前后比较采用配对t检验;计数资料组间比较采用χ2检验。结果 2组治疗后ALT、AST水平均较同组治疗前明显改善,差异均有统计学意义(P值均<0.05);与治疗前比,治疗组HOMA-IR、NAFLDFS治疗后均明显下降,差异均有统计学意义(3.58±0.85 vs 2.48±0.78,t=6.40,P<0.05;-1.78±1.24 vs-2.35±0.98,t=2.40,P<0.05)。2组间治疗后比较,治疗组HOMA-IR、NAFLDFS较对照组显著下降,差异均有统计学意义(2.48±0.78 vs 3.09±0.89,t=3.36,P<0.01;-2.35±0.98 vs-1.48±1.08,t=3.80,P<0.01)。整个疗程未见明显不良反应。结论强肝胶囊不仅能降低血清转氨酶水平,还可改善胰岛素抵抗和减轻NAFLD患者肝纤维化程度。展开更多
目的通过Meta分析考察强肝胶囊对非酒精性脂肪性肝病患者的疗效及安全性。方法检索中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、维普期刊数据库(VIP)、万方数据库、Pubmed、Medline、Web of Science、Embase中的相关随机...目的通过Meta分析考察强肝胶囊对非酒精性脂肪性肝病患者的疗效及安全性。方法检索中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、维普期刊数据库(VIP)、万方数据库、Pubmed、Medline、Web of Science、Embase中的相关随机对照试验,时间为建库至2017年10月10日。2名研究者按照纳入及排除标准筛选文献,提取数据,通过Review Manage 5.2软件进行Meta分析。结果共纳入15项研究,1 460例患者。治疗组(单纯应用强肝胶囊或联合其他药物)在改善丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、谷氨酰转肽酶(GGT)、甘油三酯(TG)、肝脾CT比值方面均显著优于对照组(不应用强肝胶囊的治疗手段)(P<0.05),但对总胆固醇(TC)的疗效不显著(P>0.05)。同时,治疗组不良反应发生率低于对照组。结论强肝胶囊对非酒精性脂肪性肝病患者疗效确切,安全性高。展开更多
文摘Objective:To study the effect of Qianggan Pills combined with antiviral treatment on the fibrosis indexes, immune and inflammatory response in patients with compensated hepatitis b cirrhosis.Methods:A total of 88 patients with compensated hepatitis b cirrhosis treated in our hospital between April 2013 and March 2016 were collected and divided into observation group and control group according to single blind randomized control. Observation group of patients accepted Qianggan Pills combined with antiviral treatment and control group of patients received antiviral treatment alone. After 6 months of treatment, chemiluminescence method was used to detect serum fibrosis indexes, flow cytometer was used to detect peripheral blood T lymphocyte subset levels, and enzyme-linked immunosorbent assay (ELISA) was used to detect serum levels of inflammatory factors.Results: Before treatment, differences in fibrosis indexes, immune and inflammatory response indexes were not statistically significant between two groups of patients;after 6 months of treatment, serum LN, HA andⅣ-C levels of observation group were lower than those of control group, peripheral blood CD3+ and CD4+T lymphocyte levels as well as CD4+/CD8+ ratio were higher than those of control group, and CD8+ T lymphocyte level was lower than that of control group;serum PCT and CRP levels were lower than those of control group while IL-10 and IL-13 levels were higher than those of control group.Conclusion:Qianggan Pills combined with antiviral treatment can inhibit the fibrosis process, strengthen the body's immune function and also relieve systemic inflammatory response in patients with compensated hepatitis b cirrhosis.
文摘Objective： To observe the therapeutic effect and safety of Qianggan Capsule （强肝胶囊, QGC） in treating non-alcoholic fatty liver disease （NAFLD）, using potyene phosphatidylcholine capsule （PPC） as a reference. Metheds： Eighty-eight patients with NAFLD were randomly assigned to two groups, 45 in the treatment group treated with QGC and 43 in the control group treated with PPC. The course of treatment tasted for 6 months. Changes in liver function, blood lipids, and iconographic indexes before and after treatment were observed, and clinical efficacy was evaluated. Results： In the treatment group, alanine aminotransferase （ALT） was towered significantly from 56.02 ± 32.59 lUlL before treatment to 38.27 ± 22.68 IU/L after treatment, and CT liver/spleen ratio significantly increased from 0.69± 0.18 to 0.91 ± 0.25, showing statistical significance （P〈0.05）; in contrast, the corresponding changes of the two indexes in the control group were 56.56 ±26.33 IU/L to 49.67 ± 26.22 IU/L, and 0.66± 0.20 to 0.75 ± 0.24, respectively, the pre-post treatment difference showing insignificant difference （P〉0.05）. No severe adverse reactions occurred during the whole treatment course. Conclusion： QGC is an effective and safe remedy for the treatment of NAFLD.
基金Item of the key program of Science and Technique of Zhanjiang City(No.200068)
文摘Objective:To explore the clinical therapeutic effect of Qianggan Capsule(QGC)in treating chronic hepatitis B with liver fibrosis from the pathological aspect.Methods:Sixty three patients of chronic hepatitis B with liver fibrosis were randomly divided into the treated group(n=45)and the control group(n=18).Both groups were treated with general liver protective drugs,such as Glucurone and vitamins B complex for 6 months.To the treated group,QGC was used additionally.The levels of serum alanine transaminase and liver fibrosis indexes including hyaluronic acid(HA),collagen typeⅣ(CⅣ)and laminin(LN)as well as the pathological examination of liver biopsy were observed before and after treatment.Results:The liver cirrhosis indexes,HA,CⅣand LN,were improved significantly in the treated group after treatment,P<0.05.The liver function improvement rate in the treated group and the control group was 90.3%and 66.7%respectively,comparison of the two groups showed insignificant difference,P>0.05.Pathological examination showed that the effective rate of treatment on liver inflammatory necrosis activity grade in the treated group was 57.8%and that on liver fibrosis stage was 75.6%,which were significantly improved as compared with those before treatment(P<0.05 and P<0.01),while in the control group,no significant improvement was found after treatment(P>0.05).Conclusion:QGC has marked effects in reversing liver fibrosis and alleviating hepatic inflammatory necrosis in patients of chronic hepatitis B with liver fibrosis,and could lower the serum liver fibrosis related indexes effectively.
基金supported by grants from the National Science and Technology Major Project (No.2017ZX09301-068)National Natural Science Foundation of China (No.81620108030)the Shanghai innovation project of TCM (No.ZYKC201601005)。
文摘Objective: Qianggan(QG) extract is a patented traditional Chinese medicine that has been widely used for the clinical treatment of nonalcoholic steatohepatitis(NASH). However, its mechanism remains unclear. Methods: The efficacy of QG was evaluated in mice with methionine-and-choline-deficient diet-induced NASH by measuring serum alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels and by H and E staining of liver sections. Microarray and bioinformatics analyses were performed to obtain hepatic micro RNA(mi RNA) and m RNA expression profiles and to mine potential mechanisms and therapeutic targets. Furthermore, representative mi RNA and m RNA expression levels were validated by quantitative real-time polymerase chain reaction(q RT-PCR). Results: QG extract significantly improved NASH. Twelve differentially expressed mi RNAs and 1124 differentially changed m RNAs were identified as potential targets of QG extract. Integrated analysis detected 976 mi RNA–m RNA regulatory pairs, and networks including 11 mi RNAs and 427 m RNAs were constructed by Cytoscape. Hub nodes including mi R-7050-5p, mi R-212-3p, Bcl2l11, and Kras were filtered out. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses revealed that 427 m RNAs were enriched in pathways including apoptotic process, immune response, Fox O signaling pathway, and natural killer cell-mediated cytotoxicity. We also constructed a protein–protein interaction network with 254 nodes, and identified hub genes including Kras, Fasl, and Ncam1. Finally, the results of q RT-PCR were in good accordance with microarray data. Conclusion: This study identified important hub mi RNAs and m RNAs involved in the mechanism of QG extract and which might provide potential therapeutic targets for patients with NASH.
文摘基于多靶点虚拟筛选、网络药理学分析和体外实验,探讨强肝胶囊(QGC)治疗非酒精性脂肪性肝病(NAFLD)的潜在作用机制。利用基于PPARα/γ、FXR及sEH的多靶点虚拟筛选选出QGC中具有治疗NAFLD的活性成分,运用网络药理学预测活性成分靶点、疾病相关靶点,筛选调控疾病的关键靶点,通过Discovery Studio 2020软件和Gromacs软件对关键活性成分和关键靶点进行分子对接和分子动力学模拟分析。最后,通过实验验证QGC中的关键活性成分对肝细胞脂肪变性的改善作用。多靶点虚拟筛选得到235个QGC活性成分,网络药理学分析得到320个成分-疾病共同靶点。分子对接结果表明,芹菜素、异鼠李素、迷迭香酸、大黄素甲醚、木犀草素与关键靶点PTPN1、PPARα、PPARγ、AR具有良好的结合能力。分子动力学模拟进一步验证了迷迭香酸、大黄素甲醚等化合物与关键靶点具有良好的结合稳定性。体外实验结果显示,5个关键活性成分均能改善HepG2细胞的脂肪变性,其中异鼠李素、迷迭香酸、大黄素甲醚改善细胞脂肪变性模型的效果最佳。本研究通过多层面探讨,为QGC在NAFLD治疗中的开发和应用提供理论依据。
文摘目的观察强肝胶囊对非酒精性脂肪性肝病(NAFLD)患者肝纤维化评分和胰岛素抵抗指数的影响。方法选取2014年8月-2015年7月在上海市第八人民医院就诊的NAFLD患者85例,随机分为治疗组(n=45)和对照组(n=40)。治疗组给予强肝胶囊,对照组给予多烯磷脂酰胆碱胶囊,2组疗程均为24周。观察2组治疗前后血清转氨酶(AST、ALT)、稳态模型胰岛素抵抗指数(HOMA-IR)以及NAFLD肝纤维化评分(NAFLDFS)的变化。计量资料组间比较采用成组t检验,组内治疗前后比较采用配对t检验;计数资料组间比较采用χ2检验。结果 2组治疗后ALT、AST水平均较同组治疗前明显改善,差异均有统计学意义(P值均<0.05);与治疗前比,治疗组HOMA-IR、NAFLDFS治疗后均明显下降,差异均有统计学意义(3.58±0.85 vs 2.48±0.78,t=6.40,P<0.05;-1.78±1.24 vs-2.35±0.98,t=2.40,P<0.05)。2组间治疗后比较,治疗组HOMA-IR、NAFLDFS较对照组显著下降,差异均有统计学意义(2.48±0.78 vs 3.09±0.89,t=3.36,P<0.01;-2.35±0.98 vs-1.48±1.08,t=3.80,P<0.01)。整个疗程未见明显不良反应。结论强肝胶囊不仅能降低血清转氨酶水平,还可改善胰岛素抵抗和减轻NAFLD患者肝纤维化程度。
